November 18, 2005

Dear Valued Mallinckrodt Customer:

Mallinckrodt initiated a voluntary recall today of our Ultra-TechnetKow® DTE Generator (Technetium Tc-99m Generator). This voluntary recall will affect generator availability for a minimum of six weeks from the date of the recall. Due to the significant impact of this action to the nuclear medicine industry, we feel it is our responsibility to provide some relevant information on the production interruption, the actions taking place to correct the situation and the impact to our customers.

This voluntary recall is being conducted as a result of issues identified during routine sterility assurance process re-validation. Mallinckrodt has not received any reports of adverse events involving patient health or safety to prompt this recall. The required re-validation processes will take a minimum of six weeks to complete. Mallinckrodt is committed to taking whatever steps are necessary to ensure the safety of all our products, and will strive to resume production as soon as possible.

Mallinckrodt has been working diligently with alternate manufacturers and pharmacy chains to assist in procurement of generator supply. We are also working with industry leadership to communicate these issues and develop temporary solutions to most effectively and expeditiously manage through this shortage.

To maximize available technetium for patient use and manage this temporary shortage, please consider rescheduling non-critical procedures, injecting lower activities of technetium-based radiopharmaceuticals, where medically appropriate, and utilizing alternate isotopes or modalities for critical procedures. In order to provide alternative isotopes, we have bolstered our thallium production to allow for substitution in myocardial procedures.

Thank you for your support during this difficult market situation. Please contact your local sales representative or Mallinckrodt pharmacy for additional information.

Sincerely,

Steve Hanley
President
Imaging Division